Diabetes Vaccine : The Next Big Thing in Pharma Industry

Google+ Pinterest LinkedIn Tumblr +

Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus called coxsackievirus B1, wherein it senses enterovirus and produces immune response to destroy it. It destroys the insulin producing beta cell in pancreas, which is linked with type 1 diabetes. Though currently there is no approved diabetes vaccine available, however, key players are focusing on research to develop such vaccines by targeting various mechanisms that triggers the autoimmune response.

High global prevalence of type 1 diabetes is expected to aid in growth of the market over the forecast period

High global prevalence and incidence of type 1 diabetes is, inadvertently expected to create a conducive environment for growth of the diabetes vaccine market. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide by end of 2017. Of this, one million people (children and adolescents below 20 years of age) are suffering from type 1 diabetes, with around 150,000 new cases reported each year.

Furthermore, patients suffering from type 1 diabetes need constant monitoring and may also require insulin externally, which has to be taken intramuscularly every day. This becomes difficult for children. Cost associated with insulin therapy is also relatively high. These are expected to be factors supporting growth of the market.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1367

Diabetes Vaccine Market Taxonomy

On the basis of age group, the global diabetes vaccine market is segmented into:

  • Up to 20 years of age
  • Above 20 years of age

On the basis of end user, the global diabetes vaccine market is segmented into:

  • Hospitals
  • Clinics
  • Others

North America market is expected to exhibit high growth, followed by Europe and Asia Pacific markets over the forecast period

North America is expected to exhibit high growth in the global diabetes vaccine market over the forecast period. This is owing to increasing incidence of diabetes and high resultant healthcare burden in the U.S. For instance, according to IDF, 17,100 new cases were detected in 2017 in the U.S. Around US$ 377 billion was spent over entire diabetes disease range, which accounts for about 52% of the total healthcare expenditure on diabetes worldwide. Significant part of which goes into maintaining constant blood sugar in type 1 by use of insulin. According to statistics released by American Diabetes Association, in 2017, around 193,000 people under 20 years of age in the U.S. were estimated to be diagnosed with diabetes, which accounts for 0.24% of this population. This inadvertently, is expected to create a conducive environment for growth of the market. U.S. has maximum number of children and adolescent(under age 20) with Type 1 diabetes at range of 1,69,600 in 2017,this is followed by  India with highest cases  type 1 diabetes after the U.S at range of 1,28,500 as reported by IDF.

Developments in the diabetes vaccine market

  • Imcys— a Belgium-based biotech company— announced plans to commence its clinical trial in 2018 for new diabetes vaccine to treat type 1 diabetes. It uses modified peptides called imotopes, which spurs specific type of immune cell to kill immune cells that work on the insulin producing beta cells.
  • Moreover, in 2017, Massachusetts General Hospital Immunobiology Laboratory presented findings of clinical trial at 75th Scientific Sessions of the American Diabetes Association, related to use of BCG vaccine to treat autoimmune response in type 1 diabetes. BCG vaccine could induce a permanent gene expression that restores regulatory T cells, thereby preventing the immune system attack, which is observed in type 1 diabetes. It is currently under phase two clinical trial.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/1367

 

Share.

About Author

Is an excellent researcher with expertise in the healthcare domain. His detailed research on topics related to recent breakthroughs in the genetic engineering, pharmacy, and healthcare fields coupled with his ability to concise his in-depth study in the best way possible, is of great advantage to this new portal. Contact Author

Comments are closed.